A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas
A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas
The first indication of hysterectomies in France are uterine leiomyomas. When they are
 symptomatic leiomyomas are particularly responsables of an increase of menstruations duration
 and volume. Echography is the reference exam for the diagnosis. It exists two treatments
 ways:-firstly progestatives and antifibrinolytics for the treatment of hemorragic symptoms,
 -secondly LH-RH analogs for the treatment of leiomyomas volume and hemorragic symptoms but
 just used for a small period because of the risk of osteoporosis.

 Different studies with different doses of mifepristone were released. The authors observe a
 decrease of leiomyomas volume. Based on this experience the present placebo controlled study
 has for objectives:-to confirm the efficacy of 10 mg oral mifepristone during 24 weeks in the
 volume decrease and in symptoms of leiomyomas, - to assess the safety of the treatment. The
 aim is to avoid or delay the hysterectomy of non menopausal patients. During the study
 patients will be evaluated with biological exams, clinical exams, echographies, medical
 interrogations and their diary cards.
Inclusion Criteria:

 -  patients who are willing and able to participate in the study

 -  patients from whom written informed consent has been obtained

 -  patients who contribute to the National Insurance Scheme

 -  patients with an age between 25 and 49 years old

 -  non menopausal patients

 -  patients who use a non hormonal contraception

 -  patients with one or several , interstitial or subserous, uterine leiomyomas

 -  echographic diameter of leiomyomas must be equal or higher than 30 mm

 -  leiomyomas must be symptomatic